Study links high serum enzyme to liver cancer:
This article was originally published in Clinica
Measuring the level of an enzyme in serum could help doctors identify which patients with hepatitis C virus-associated cirrhosis are at risk of rapidly developing liver cancer, according to a Japanese team. A seven-year follow-up study, published in Cancer (August 15), showed that the five-year incidence rate of hepatocellular carcinoma was 53.6% in patients with persistently high levels of the enzyme alanine aminotransferase (ALT) compared with 7.1% in those with persistently low levels of the enzyme. The team suggested that patients with high serum ALT levels may benefit from intensive surveillance using medical imaging.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.